View in EDS

EE282 Quality-Adjusted Life Year (QALY) Results From a Cost-Effectiveness Model for Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Relapsed/Refractory Multiple Myeloma (RRMM).

Saved in:
Bibliographic Details
Title: EE282 Quality-Adjusted Life Year (QALY) Results From a Cost-Effectiveness Model for Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Relapsed/Refractory Multiple Myeloma (RRMM).
Authors: Kaiser, Martin1 (AUTHOR), Suvannasankha, Attaya2 (AUTHOR), Lee, Dawn3 (AUTHOR), Dlotko, Ewa4 (AUTHOR), Macleod, Paul4 (AUTHOR), Boytsov, Natalie5 (AUTHOR), Crossman-Morgan, Christina-Jane6 (AUTHOR), Jadhav, Vinay7 (AUTHOR), Kazeem, Gbenga8 (AUTHOR), Lloyd, Connor6 (AUTHOR), Purser, Molly5 (AUTHOR), Riemer, Justin9 (AUTHOR), SAMYSHKIN, Yevgeniy6 (AUTHOR), McNamara, Simon8 (AUTHOR)
Source: Value in Health. 2025 Supplement 1, Vol. 28 Issue 6, pS114-S115. 2p.
Database: Academic Search Ultimate
Description
ISSN:10983015
DOI:10.1016/j.jval.2025.04.1881